Oruka Therapeutics director Ball sells 18,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Oruka Therapeutics director Kristine M. Ball exercised options to acquire 18,000 common shares on November 12, 2026, at $6.84 per share, and sold 18,000 shares in six transactions. The reported weighted-average sale prices ranged from $102.0967 to $106.9850 per share. The sales were made under a Rule 10b5-1 trading plan entered into August 12, 2026. Following the exercise, 53,426 shares underlying options were reported.
Insider Trade Summary 10b5-1
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F8 | 18,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 18,000 | $6.84 | $123K |
| Sale | Common Stock F1, F2 | 1,196 | $102.0967 | $122K |
| Sale | Common Stock F1, F3 | 1,300 | $103.0932 | $134K |
| Sale | Common Stock F1, F4 | 2,039 | $104.1622 | $212K |
| Sale | Common Stock F1, F5 | 10,765 | $105.3141 | $1.13M |
| Sale | Common Stock F1, F6 | 2,500 | $106.052 | $265K |
| Sale | Common Stock F1, F7 | 200 | $106.985 | $21K |
Footnotes (8)
- F1. These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.62 to $102.61, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.66 to $103.65, inclusive.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.69 to $104.65, inclusive.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.76 to $105.75, inclusive.
- F6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.76 to $106.46, inclusive.
- F7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.97 to $107.00, inclusive.
- F8. The option vests as to 1/4 of the underlying shares on May 7, 2025 and as to 1/48 of the underlying shares monthly from May 7, 2025.
Key Figures
Key Terms
Rule 10b5-1 trading plan regulatory
weighted average price financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.